PLIANT THERAPEUTICS, INC. - Common stock, par value $0.0001 per share (the "Shares") (PLRX) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2020 to Q4 2025

Type / Class
Equity / Common stock, par value $0.0001 per share (the "Shares")
Symbol
PLRX on Nasdaq
Shares outstanding
61,059,490
Price per share
$1.22
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
50,406,732
Total reported value
$74,592,710
% of total 13F portfolios
0%
Share change
-912,437
Value change
+$1,536,227
Number of holders
97
Price from insider filings
$1.22
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of PLIANT THERAPEUTICS, INC. - Common stock, par value $0.0001 per share (the "Shares") (PLRX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
TANG CAPITAL MANAGEMENT LLC 9.6% $7,382,395 5,859,044 TANG CAPITAL MANAGEMENT, LLC 03 Mar 2025
Woodline Partners LP 7.3% $6,667,129 4,504,817 Woodline Partners LP 30 Sep 2025
Point72 Asset Management, L.P. 6.7% $6,617,728 4,085,017 Point72 Asset Management, L.P. 27 Aug 2025
VANGUARD GROUP INC 4.9% $4,143,240 3,002,348 The Vanguard Group 30 Jun 2025
CITADEL ADVISORS LLC 4.9% $3,650,136 2,991,915 Kenneth Griffin 14 Jan 2026
Redmile Group, LLC 4.8% $3,648,302 2,895,478 Redmile Group, LLC 31 Dec 2024
BlackRock, Inc. 3.4% $2,904,312 2,104,574 BlackRock, Inc. 30 Jun 2025
MORGAN STANLEY 0.9% -87% $861,460 -$5,043,529 545,228 -85% Morgan Stanley 31 Dec 2025
FMR LLC 0.2% $166,312 131,993 FMR LLC 28 Feb 2025
PRICE T ROWE ASSOCIATES INC /MD/ 0.1% $110,469 87,674 T. Rowe Price Associates, Inc. 31 Mar 2025

As of 30 Sep 2025, 97 institutional investors reported holding 50,406,732 shares of PLIANT THERAPEUTICS, INC. - Common stock, par value $0.0001 per share (the "Shares") (PLRX). This represents 83% of the company’s total 61,059,490 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of PLIANT THERAPEUTICS, INC. - Common stock, par value $0.0001 per share (the "Shares") (PLRX) together control 74% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
TANG CAPITAL MANAGEMENT LLC 9.8% 6,003,446 +0.06% 0.34% $8,885,100
Woodline Partners LP 7.4% 4,504,817 +92% 0.03% $6,667,129
Point72 Asset Management, L.P. 7.1% 4,338,394 0.01% $6,420,823
MORGAN STANLEY 5.7% 3,507,288 -6.6% 0% $5,190,785
Blue Owl Capital Holdings LP 4.9% 2,969,199 0% 1.4% $4,394,415
VANGUARD GROUP INC 4.5% 2,775,938 -7.5% 0% $4,108,388
ACADIAN ASSET MANAGEMENT LLC 3.9% 2,369,542 +45% 0.01% $3,501,000
CITADEL ADVISORS LLC 3.8% 2,339,468 -0.7% 0% $3,462,413
JPMORGAN CHASE & CO 3.5% 2,130,489 +8.8% 0% $3,153,123
Redmile Group, LLC 2.6% 1,591,695 -2.5% 0.23% $2,355,709
BlackRock, Inc. 2.3% 1,420,863 -33% 0% $2,102,878
UBS Group AG 2.2% 1,322,017 -50% 0% $1,956,585
Peapod Lane Capital LLC 1.8% 1,097,028 +23% 1.5% $1,623,616
TWO SIGMA ADVISERS, LP 1.8% 1,072,500 +136% 0% $1,587,300
RENAISSANCE TECHNOLOGIES LLC 1.7% 1,011,802 +406% 0% $1,497,467
GREAT POINT PARTNERS LLC 1.4% 850,000 0% 0.53% $1,258,000
Eversept Partners, LP 1.4% 824,594 0.09% $1,220,399
Monaco Asset Management SAM 1.3% 822,693 +17% 0.45% $1,217,586
TWO SIGMA INVESTMENTS, LP 1.3% 783,255 +182% 0% $1,159,217
BANK OF AMERICA CORP /DE/ 1.2% 708,056 +47% 0% $1,047,923
GEODE CAPITAL MANAGEMENT, LLC 0.96% 587,409 +0.83% 0% $869,823
GOLDMAN SACHS GROUP INC 0.91% 555,076 -7% 0% $821,512
MILLENNIUM MANAGEMENT LLC 0.88% 537,337 -37% 0% $795,259
BESSEMER GROUP INC 0.87% 532,079 -0.01% 0% $787,000
XTX Topco Ltd 0.76% 466,984 +8.9% 0.04% $691,136

Institutional Holders of PLIANT THERAPEUTICS, INC. - Common stock, par value $0.0001 per share (the "Shares") (PLRX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 227,082 $277,081 -$23,806 $1.22 4
2025 Q3 50,406,732 $74,592,710 +$1,536,227 $1.48 97
2025 Q2 51,491,424 $59,725,484 -$8,565,210 $1.16 112
2025 Q1 57,869,854 $78,125,725 -$216,550,058 $1.35 138
2024 Q4 64,754,179 $852,599,577 +$21,507,886 $13.17 158
2024 Q3 63,483,171 $714,277,262 -$5,640,125 $11.21 150
2024 Q2 63,899,830 $686,916,488 -$18,528,903 $10.75 142
2024 Q1 65,187,162 $971,257,840 +$42,313,749 $14.90 134
2023 Q4 42,318 $766,379 -$1,361,309 $18.11 1
2023 Q3 60,161,028 $1,043,150,864 +$26,908,266 $17.34 134
2023 Q2 58,042,121 $1,051,734,567 +$10,370,393 $18.12 141
2023 Q1 56,237,135 $1,495,380,765 +$312,492,532 $26.60 143
2022 Q4 44,665,353 $863,362,398 -$10,785,771 $19.33 120
2022 Q3 45,349,244 $947,339,021 +$330,410,977 $20.89 104
2022 Q2 30,128,550 $241,325,678 -$11,149,214 $8.01 79
2022 Q1 31,409,886 $220,225,413 +$4,177,142 $7.01 80
2021 Q4 30,219,739 $407,963,043 +$2,290,575 $13.50 77
2021 Q3 30,380,086 $512,798,759 -$16,848,210 $16.88 75
2021 Q2 30,676,187 $893,272,740 -$1,341,916 $29.12 80
2021 Q1 30,711,599 $1,207,818,215 +$63,161,590 $39.33 75
2020 Q4 27,997,313 $636,120,804 +$5,703,351 $22.72 53
2020 Q3 27,754,476 $625,749,229 +$21,482,334 $22.65 52
2020 Q2 350,000 $8,918,000 +$8,918,000 $25.48 1